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Objectives.  The purpose of this study was to determine the current status of ß-
lactamase-producing bacteria in orofacial odontogenic infections.  
Study design.  Microbiological data from pus specimens of 111 cases with 
orofacial odontogenic infections were analyzed in relation to the past 
administration of ß-lactams in the enrolled infections.   
Results.  ß-lactamase-producing bacteria were isolated more frequently from the 
ß-lactam-administered group (38.5%) than from the ß-lactam-nonadministered 
group (10.9%) (P < .005), and they were isolated more frequently as the duration 
of administration increased.  The predominant bacteria isolated included 
Prevotella, the most frequent isolate, viridans streptococci, Peptostreptococcus, 
and Fusobacterium, and  7.1% of total isolates produced ß-lactamase.  Penicillin 
and cefazolin worked well with ß-lactamase-nonproducing Prevotella, but were 
remarkably affected by ß-lactamase-producing Prevotella. Cefmetazole, 
sulbactam/cefoperazone, and imipenem worked well against both kinds of 
Prevotella.  
Conclusions.  ß-lactams are still suitable for the first antimicrobial therapy in the 
treatment of the infections.  However, since past ß-lactam administration 
increases the emergence of ß-lactamase-producing bacteria, ß-lactamase-stable 
antibiotics should be prescribed to patients with unresolved infections who have 






For the treatment of orofacial odontogenic infections, the ß-lactam antibiotics 
are recommended because they work well against the specific bacterial causative 


























1-6   Additionally, treatment with ß-lactam antibiotics is cost-effective.  A 
problem with antimicrobial therapy with ß-lactams is the increasing rates of ß-
lactam resistance, which lead to treatment failures.3-6   ß-lactam resistance is 
considered to be closely correlated with the emergence of ß-lactamase producing 
bacteria. 3-9   There have been many reviews of orofacial odontogenic infections 
stressing the importance of ß-lactamase-producing bacteria in ß-lactam 
resistance. 3-6   Surprisingly, however, very little data regarding the occurrence of 
ß-lactamase-producing bacteria in orofacial odontogenic infections, on which the 
reviews should be based, is available.  Most of the examinations of ß-lactamase-
producing bacteria have been limited to a few bacterial species or to periodontal 
disease.10-14   We therefore determined that data regarding the current status of 
the occurrence of ß-lactamase-producing bacteria in orofacial odontogenic 
infections were required.   
Purulent orofacial odontogenic infections can be managed by tooth extraction, 
endodontic therapy, and surgical treatment, including drainage, without the use 
of antibiotics.1,3-5   However, when acute bacterial infection has progressed, or 
when antimicrobial therapy might benefit patients, antibiotics are prescribed.  In 
Japan, when acute odontogenic infections except pulpitis and gingivitis simplex 
are diagnosed or strongly suspected, almost all oral surgeons prescribe 
antibiotics in the course of the treatment to ensure the efficacy of treatment, or 



























  In Japan, oral surgeons in large hospitals and medical centers are often referred 
the patients with unsolved infections from other oral surgeons or doctors.   The 
oral surgeons should take into account the past administration of antibiotics for 
orofacial odontogenic infections.  To effectively administer antimicrobial 
therapy for patients, microbiological data from an individual pus specimen must 
be obtained.  Generally, however, it takes several days or longer to obtain the 
necessary data, and we therefore frequently start empiric antimicrobial therapy.  
For this reason, it is necessary to establish a principle regimen of empiric 
antimicrobial therapy for orofacial odontogenic infections, including cases 
treated with antibiotics in the past.   
  To address these issues, we investigated the relationships between the past 
administration of ß-lactam antibiotics, the emergence of ß-lactamase-producing 
pathogens, and the antimicrobial susceptibility of the isolates from pus 
specimens of orofacial odontogenic infections.  Our results show that Prevotella 
has the highest incidence of ß-lactamase production in frequent isolates, and that 
the past administration of ß-lactam antibiotics increases the isolation of ß-
lactamase-producing bacteria.  Furthermore, based on the results, we discuss a 
regimen of antimicrobial chemotherapy for the effective treatment of orofacial 
odontogenic infections.  
 
MATERIAL AND METHODS 
Patients 
  The case histories of a total of 111 patients with obstructed abscesses caused by 
orofacial odontogenic infections were investigated.  All patients were treated at 



























Patients who required serious medical care (e.g., cases with diabetes mellitus, 
rheumatoid arthritis, respiratory tract infections, leukemia) were excluded.  The 
types of infection observed were dentoalveolar infections, 95 cases; 
periodontitis, 8 cases; and pericoronitis, 8 cases.   
The subjects were classified into two groups: the ß-lactam (+) group and the ß-
lactam (-) group.  The former had received ß-lactam antibiotics for the treatment 
of orofacial odontogenic infections prior to the pus collection for this study.  The 
administration of ß-lactams had occurred once in the course of the infection 
within 8 days prior to the pus collection.  The patients had received only ß-
lactam antibiotics during the course of their infections and had not been 
administered any additional antibiotics within the previous 3 months.  A total of 
65 cases belonged to the ß-lactam (+) group.  The types of infection included 
were dentoalveolar infections, 56 cases; periodontitis, five cases; and 
pericoronitis, four cases.  The average age of this group was 40.3 years (range 7-
77 years).  ß-lactam antibiotics were prescribed to 47 patients in our hospital, 
and to 18 patients at other hospitals and private practices.  The ß-lactam 
antibiotics administered to the patients were oral-penicillin, four cases; 
intravenous-penicillin, two cases; oral-first-generation cephalosporin, six cases; 
intravenous-first-generation cephalosporin, one case; intravenous-second-
generation cephalosporin, 21 cases; oral-third-generation cephalosporin, 27 
cases; intravenous-third-generation cephalosporin, two cases; and carbapenem, 
two cases.  The appropriateness of the use of antibiotics, including the dose and 
duration, was confirmed by the authors.  The other group was the ß-lactam (-) 
group, who had not received any antibiotics within 3 months prior to the pus 



























The average age was 48.7 years (range 18-85 years).  The types of infection 
included were dentoalveolar infections, 39 cases; periodontitis, three cases; 
pericoronitis, four cases.  Information regarding the past and physical histories 
of the patients were obtained by interview and from the medial records of our 
hospital, if they existed.  When patients were treated for orofacial odontogenic 
infections by doctors other than the authors, we interviewed the doctors 
regarding the patient histories.  
This study was performed based on the permission of all patients who 
participated.  
 
Bacterial quantitative examination 
  The pus specimens were collected from the abscesses by aspiration with an 18-
gauge needle.  The specimens were placed in anaerobic transport devices (Seed 
Tube; Eiken, Tokyo, Japan) and immediately transported to the laboratory.  The 
specimens were incubated on Brucella HK agar (Kyokuto, Tokyo, Japan) with 
5% sheep blood in an atmosphere of 5% CO2 , 10% H2 , and 85% N2   at 37°C for 
78 h.  At the same time, the same specimens were aerobically incubated on 
Brucella HK agar with 5% sheep blood, and on the same agar in an atmosphere 
of 10% CO2 , 20% H2 , and 70% N2  at 37°C for 48 h.  Even when no bacteria 
growth was observed, incubation was continued for at least 7 days.  Anaerobic 
bacteria were identified using Rap ID ANAⅡ  (Innovative Diagnostic System, 
Norcross, GA).  In addition to this test, gas liquid chromatography was 
performed as needed to identify bacteria. 15   Aerobic and micro-aerophilic 
bacteria were identified using conventional methods.16   Bacterial strains were 





























  Nitrocefin disks (Cefinase disk; BBL Microbiology Systems, Cockeysville, 
MD) were inoculated with a small portion of growth from the Brucella blood 
agar plates described above and observed for a change in color from yellow to 
red. 17    
 
Susceptibility test 
  Antibiotics were obtained from their manufacturers as laboratory powders, each 
of a defined potency: penicillin G (Banyu, Tokyo, Japan), ampicillin (Meiji, 
Tokyo, Japan), cefazolin (Fujisawa, Tokyo, Japan), cefmetazole (Sankyo, Tokyo, 
Japan), sulbactam/cefoperazone (Pfizer, Tokyo, Japan), and imipenem (Banyu).  
All minimum inhibitory concentrations (MICs) were determined by the agar 
dilution method recommended by the National Committee for Clinical 
Laboratory standards 18 ; the MICs of anaerobes were determined using the 
Brucella HK agar with 5% sheep blood in an atmosphere of 5% CO2, 10% H2 , 
and 85% N2 at 37°C for 48 h.  The susceptibility breakpoints were determined on 
the basis of the propositions of the National Committee for Clinical Laboratory 
standards 18 ; the breakpoints used were 2.0 µg/ml for penicillin G and ampicillin, 
8.0 µg/ml for cefazolin, 16.0 µg/ml for cefmetazole and sulbactam/cefoperazone, 
and 4.0 µg/ml for imipenem. 
 
Statistical analysis 
  Statistical comparisons of the incidence of ß-lactamase-producing bacteria and 





























ß-lactamase-producing bacteria were isolated in 25 of 65 cases (38.5%) in the 
ß-lactam (+) group, while in only five of 46 cases (10.9%) in the ß-lactam (-) 
group.  The incidence of the isolation of ß-lactamase-positive bacteria in the ß-
lactam (+) group was significantly higher than in the ß-lactam (-) group (P 
< .005) (Table I).  Furthermore, we found a correlation between the incidence of 
the isolation of ß-lactamase-producing bacteria and the duration of the past 
administration of ß-lactams (Table I).  The incidence of isolation of ß-lactamase-
producing bacteria was low in the patients who had received ß-lactam for 1 or 2 
days.  However, as the administration duration increased, ß-lactamase-producing 
bacteria were isolated more frequently.  It is interesting that both patients who 
received ß-lactam for 8 days had ß-lactamase-producing bacteria.  
A total of 449 strains of bacteria were isolated from the 111 cases (Table II).  
Out of a total of 449 isolates, 32 (7.1%) were ß-lactamase-positive strains.  
Twenty-nine of 266 isolates (10.9%) and three of 183 isolates (1.6%) were ß-
lactamase-producing bacteria in the ß-lactam (+) and in the ß-lactam (-) groups, 
respectively.  This difference was significant (P < .001).  A distinct difference in 
the variety of bacterial species isolated between the ß-lactam (+) and ß-lactam (-) 
groups was not observed.  Prevotella, viridans streptococci, Peptostreptococcus, 
and Fusobacterium were isolated frequently (Table II).  In the isolated 
organisms, ß-lactamase-producing strains were detected in Enterobacter, 
Klebsiella, Prevotella, Porphyromonas, and Bacteroides, but no strains of the 
other species produced ß-lactamase.  All isolates of Enterobacter and Klebsiella 
produced ß-lactamase, but these species were rarely isolated.  The pigmented 
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Prevotella (P. intermedia, P. melaninogenica, and P. loescheii) and 
nonpigmented Prevotella (P. oralis, P. oris, and P. buccae) were isolated 
frequently, and a significant number of these isolates produced ß-lactamase: 
27.3% (18 of 66) of pigmented Prevotella strains and 16.7% (7 of 42) of 
nonpigmented Prevotella strains were ß-lactamase positive.  ß-lactamase-
producing strains of pigmented Prevotella, nonpigmented Prevotella, and 
Bacteroides were often found in the ß-lactam (+) group.  In particular, ß-
lactamase-producing strains of P. intermedia were isolated more frequently from 
the ß-lactam (+) group than from the ß-lactam (-) group with a significance of P 


























  ß-lactamase-producing bacteria were detected in two of four cases receiving 
oral-penicillin, in one of two cases received intravenous-penicillin, in four of six 
cases receiving oral-first-generation cephalosporin, in one of one cases receiving  
intravenous-first generation cephalosporins, in five of 21 cases receiving 
intravenous-second generation cephalosporin, in 11 of 27 cases receiving oral 
third-generation cephalosporin, in zero of two cases receiving intravenous-third 
generation cephalosporin, and in one of two cases receiving intravenous 
carbapenem.   
Since Prevotella was isolated frequently and showed a high incidence of ß-
lactamase production (Table II), the antimicrobial susceptibility of Prevotella to 
several ß-lactam antibiotics was determined (Table III).  In both pigmented 
Prevotella and nonpigmented Prevotella, the MIC (MIC50  and MIC90) values of 
penicillin G, ampicillin, and cefazolin of ß-lactamase-producing strains were 
distinctly greater than those of the nonproducing strains.  In addition, the 
susceptibility rates of ß-lactamase-producing strains in pigmented and 
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nonpigmented Prevotella were significantly smaller than those of the 
nonproducing strains (P < .03).  The MIC values of cefmetazole and 
sulbactam/cefoperazone of the ß-lactamase-producing strains in pigmented 
Prevotella were also higher than those of the non ß-lactamase-producing strains, 
but all strains were susceptible to cefmetazole and sulbactam/cefoperazone.  In 
nonpigmented Prevotella, there were little differences in the MIC values of 
cefmetazole and sulbactam/cefoperazone between ß-lactamase-producing and 
nonproducing strains, and all strains were susceptible to them.  Imipenem had 
quite low MIC values and high susceptibility rates against both pigmented and 
nonpigmented Prevotella, but there were no strict differences in MIC values or 
susceptibility rates between ß-lactamase-producing strains and nonproducing 




























  In Japan, the use of antibiotics in oral surgery is strictly regulated by the 
Ministry of Health and Welfare of Japan via the national health insurance.19   The 
costs of exceeded dose and incorrect selection of antibiotics are billed to the 
hospitals employing the oral surgeons who prescribed them, or to the surgeons 
themselves if they are owners of clinics.  Thus, to our knowledge, remarkably 
inappropriate use of antibiotics for the treatment of orofacial odontogenic 
infections is rare in Japan, although there would be differences concerning the 
management of antibiotic therapy between nations.   
  Three modes of resistance to ß-lactam antibiotics have been proposed regarding 
pathogens of the orofacial odontogenic infection: ß-lactamase production, 
barriers to target sites, and penicillin-binding proteins.7,20   ß-lactamase 
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production would protect not only ß-lactamase-producing bacteria but also the 


























21-23 : because orofacial 
odontogenic infections are polymicrobial, 2,4-6,24  the emergence of ß-lactamase-
producing bacteria may protect the nonproducing bacteria from the ß-lactam 
antibiotics.  It is well known that staphylococcal organisms and some gram-
negative bacilli can produce ß-lactamase.25-28   In the present study, ß-lactamase 
was detected in aerobic and strictly anaerobic gram-negative bacilli, while none 
of the Staphylococcus isolated produced this enzyme.  The incidence of ß-
lactamase-producing anaerobic gram-negative bacilli has been reported in 
several studies. 10-12,17  ß-lactamase is detected in 26% to 100% of pigmented 
Prevotella involving P. intermedia, P. melaninogenica, P. loescheii, 10,17  37.5% 
to 77.1% of nonpigmented Prevotella, 10,12  13% to 23.5% of F. nucleatum, 11,12,17  
and 33.3% of P. gingivalis. 12   In the present study, 27.3% of pigmented 
Prevotella, 16.7% of nonpigmented Prevotella, 0% of Fusobacterium, and only 
one strain of Porphyromonas produced ß-lactamase.  The incidence of ß-
lactamase-producing bacteria observed in this study was lower than that of 
previous studies.   
  ß-lactamase-producing bacteria resist antimicrobial chemotherapy with 
penicillins. 3-7,22   In addition, ß-lactamase produced by P. melaninogenica and P. 
oralis have been shown to be more active against penicillins than against 
cephalosporins. 7   Cefazolin is a first- generation cephalosporin.29   In general, 
the first-generation cephalosporins are affected by ß-lactamase more strongly 
than the second- or third- generation agents.  Cefmetazole is stable with ß-
lactamase and active against anaerobic bacteria. 30,31   Sulbactam/cefoperazone is 
a member of the cephalosporin family made by combining cefoperazone and 
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sulbactam, a ß-lactamase inhibitor.32   Adding sulbactam to ß-lactam antibiotics 



























7,32-34   Imipenem has an unusually broad spectrum, a high potency, a 
stability to ß-lactamase, and no cross-resistance with other ß-lactam agents.34-36 
It is interesting that the activity of test penicillins and cefazolin against ß-
lactamase-producing Prevotella was decreased remarkably in the present study, 
while these antibiotics inhibited the growth of the ß-lactamase-nonproducing 
Prevotella.  In contrast, cefmetazole and sulbactam/cefoperazone were active 
against both ß-lactamase-producing and nonproducing Prevotella.  Moreover, 
imipenem greatly inhibited the growth of ß-lactamase-producing Prevotella.   
In penicillin therapy, the relationship between exposure to penicillin and the 
emergence of ß-lactamase-producing bacteria has been discussed. 13,14,37   Brook 
et al 37 , Heimdahl et al 13 , and Kinder et al 14  have noted that the use of 
penicillin is associated with the emergence of ß-lactamase-producing bacteria, 
while the work of Lewis et al 22  dose not support this conclusion.  In the present 
study, although cephalosporins were administered more frequently than 
penicillins, ß-lactamase-producing bacteria were found more frequently in the ß-
lactam (+) group than in the ß-lactam (-) group.  Especially in Prevotella, which 
was the most frequent isolate, ß-lactamase-producing strains were found more 
frequently in the ß-lactam (+) group than in the ß-lactam (-) group.  This 
suggests that past antimicrobial therapy with ß-lactam antibiotics for an 
unresolving infection increases the incidence of ß-lactamase-producing bacteria 
in abscesses of odontogenic infections.   
We found an interesting correlation between the incidence of ß-lactamase-
producing bacteria and the duration of ß-lactam administration in the past 
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treatment in orofacial odontogenic infections.  When the duration was 1 or 2 
days, few ß-lactamase-producing bacteria emerged.  However, when patients 
received ß-lactam antibiotics for 3 days or more, 50% or more of the cases 
acquired ß-lactamase-producing bacteria.  In Japan, the daily doses of ß-lactams 
usually used for adult orofacial odontogenic infections are regulated by Health 
and Welfare of Japan.  For example, the doses for an adult (with 60 kg weight) 
are as follows: oral-ampicillin, 1 g; intravenous-ampicillin, 2 g; cephalexin, 750 


























19   
All patients in the ß-lactam (+) group received the appropriate doses.  A clear 
correlation between the incidence of ß-lactamase-producing bacteria and the type 
of antibiotics or route of administration was not found.  Further studies to 
evaluate the relations between the incidence of ß-lactamase-producing bacteria 
and the type of antibiotics, dosage, or route of administration may be required 
based on both the patient population and the microbiological population.  
However, the present study suggests that if patients with orofacial odontogenic 
infections have already received ß-lactam antibiotics for 3 days or more, 
regardless of the type of antibiotic or the route of administration, we should 
assume that ß-lactamase-producing bacteria are present in the lesion and are 
associated with infection progression.  
Based on this study, we propose a principle for developing a regimen to treat 
orofacial odontogenic infections empirically.  If the patients have not received ß-
lactam antibiotics in the course of the infections, or even if they have received ß-
lactam antibiotics with an appropriate dose for a duration of 1 day or 2 days, 
penicillins and primitive cephalosporins are suitable to prescribe, since in this 
instance there is only a small possibility of the occurrence of ß-lactamase-
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producing bacteria, and these antibiotics are considered to be effective.  In 
contrast, if the patients already received antimicrobial therapy with ß-lactams in 
the course of the infections for a duration of 3 days or more, it should be 
assumed that ß-lactamase-producing bacteria may occur or be present in the 
unsolving lesion.  In such cases, ß-lactamase-stable ß-lactams or non-ß-lactam 


























1-6,38,39   In this 
case, we recommend the primary use of ß-lactamase-stable ß-lactams, since they 
have great effectiveness against pathogens of the infection, especially 
Prevotella, Porphyromonas, and Fusobacterium, 33,34  and the occurrence of side 
effects is lower than with other antibiotics.  In addition, cost should be taken into 
account.  Many of these ß-lactamase-stable antibiotics are more expensive than 
penicillins and primitive cephalosporins. 5,40   For example, in Japan, the costs of 
cefmetazole, sulbactam/cefoperazone, and imipenem are two to five times as 
high as the cost of penicillins or primitive cephalosporins.  Moreover, to prevent 
increasing the incidence of resistance to these ß-lactamase-stable agents, they 
should not be abused.  Therefore, we do not agree with the practice of 
prescribing ß-lactamase-stable antibiotics to all patients without consideration.  
Not only Prevotella but also viridans streptococci, Peptostreptococcus, and 
Fusobacterium have been shown to be frequent isolates in orofacial odontogenic 
infections. 2,4,24,41   The resistance mechanisms of viridans streptococci and 
Peptostreptococcus against ß-lactams are rather to alter membrane permeability 
or to alter target sites (the mutation of penicillin-binding proteins) than to induce 
ß-lactamase production. 42,43   However, the regimen proposed here would be 
effective against these bacteria, including Fusobacterium, based on the 













department now employs this regimen, and satisfactory results are being obtained 
(unpublished data).   
  The results of this study and the regimen proposed here may be helpful in 
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Table I.  Correlation between the incidence of ß-lactamase-producing bacteria  








8   2/  2 (100) 
  2/  4 (50.0) 
  2/  4 (50.0) 
  2/  4 (50.0) 
15/30 (50.0) 
  0/  0  
  2/14 (14.3) 
  0/  7  
*See the text regarding this grouping.    
†No. of cases from which ß-lactamase -producing bacteria were isolated / No.  
of total cases  (percents). 
Duration (days) Incidence† 























Table II.  Incidence of ß-lactamase-producing bacteria from patients with orofacial odontogenic infections 
Bacteroides 
Incidence * Incidence *  
0/49 
0/  2 
0/  1 
0/  1 
0/  3 
0/  1 
0/  1 
1/  1 (100) 
2/  2 (100) 
0/  3 
3/ 129 (2.3)  
  0/44  
  0/16  
  0/  1 
  0/  2  
  0/  6  
0/38  
0/  1 
0/  0 
0/  3 
0/  2 
0/  3 
0/  1 
0 / 0 
0/  0 
0/  3 
0/  3 
  0/29 
  0/  9  
  0/  5  
0/  1  
0/  5  
  3/  9 (33.3) 0/  2 
Fusabacterium nucleatum   0/33 0/21 




 12/30  (40.0) §  1/14  ( 7.1) 
   4/  7   (57.1) 0/  2 
   1/10   (10.0) 0/  3 
17/47 (36.2) 1/19 ( 5.3) 
Porphyromonas gingivalis 
P. endodontalis 
  0/10  0/12 




   4/  9  (44.4) 
   1/  6  (16.7) 
   1/  9  (11.1) 
1/  7  (14.3) 
0/  3 
0/  8 
  6/24 (25.0) 1/18 ( 5.6) 
*No. of ß-lactamase-producing isolates / No. of total isolates (percents). 
†,‡ See the text regarding this grouping.   
§Statistically significant at P < .05. 
ß-lactam  (+)  
group † 
ß-lactam (-)  
group ‡  
ß-lactam  (+)  
Group † 




0/ 4   










rate(%) 50% 90% 
Susceptibility 
rate(%) 
4.0 32.0 33.3 *  ≤0.015  2.0  87.5 
0.5 64.0 61.1 * 0.06 0.5 93.8 
2.0 16.0 83.3 * ≤0.015 0.5 100 
0.5 2.0 100 ≤0.015 1.0 100 
1.0 8.0 100 ≤0.015 1.0 100 








16.0 32.0 0.0 *   0.06 0.5 100 
16.0 32.0 0.0 * 0.1 2.0 82.9 
16.0 64.0 28.6 * 0.1 1.0 100 
4.0   4.0 100 0.2 8.0 100 
2.0 2.0 100 0.5 8.0 100 
 ≤0.015   0.06 100   0.06 0.2 100 
ß-lactamase-nonporducing strains ß-lactamase-producing strains 
Pigmented Prevotella 
Non-pigmented Prevotella 
Table III. Antimicrobial susceptibility of Prevotella against ß-lactam antibiotics 
In pigmented Prevotella, 18 ß-lactamase-producing strains and 48 ß-lactamase nonproducing 
strains were tested.  In nonpigmented Prevotella, seven ß-lactamase-producing strains and 35 
ß-lactamase-nonproducing strains were tested. 
* P < .03 vs. ß-lactamase-nonproducing strains.   
MIC (µg/ml) MIC (µg/ml) 
